Table 4.
Molecular correlates among patients with tissue available for analysis (N=47)
| Pathologic Findings | N | % |
|---|---|---|
| Tissue evaluated | ||
| Pre-treatment biopsy on study | 24 | 51 |
| Archived primary tumor | 9 | 19 |
| Archived recurrence biopsy | 11 | 24 |
| Unknown | 3 | 6 |
| Immunohistochemistry | ||
| Estrogen positive | 29/32 | 91 |
| Estrogen negative | 3/32 | 9 |
| Progesterone positive | 19/30 | 63 |
| Progesterone negative | 11/30 | 37 |
| Mutation Detected by CMS50 Panel (N=47) | ||
| Yes | 47 | 100 |
| No | 0 | 0 |
| Median number of mutations (range) | 2 (1–4) | |
| Most common mutations | ||
| PTEN | 28 | 60 |
| PIK3CA | 22 | 47 |
| KRAS | 18 | 38 |
| TP53 | 12 | 26 |
| CTNNB1 | 11 | 23 |
| AKT1 | 2 | 11 |